44
Participants
Start Date
November 28, 2018
Primary Completion Date
December 31, 2023
Study Completion Date
January 1, 2027
Specialized tumor board recommendation
Based on the molecular profile, the specialized tumor board will determine an individualized treatment recommendation for each patient using up to four FDA approved drugs. In special circumstances, Investigational new drug (IND) study agents may be used.
The Children's Hospital Of Philadelphia, Philadelphia
Children's National Medical Center, Washington D.C.
Johns Hopkins University, Baltimore
University of Florida, Gainesville
Nationwide Children's Hospital, Columbus
Children's Hospitals and Clinics of Minneapolis, Minneapolis
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Washington University, St Louis
University of Utah, Salt Lake City
University of California, San Diego Rady Children's Hospital, San Diego
University of California, San Francisco, San Francisco
Seattle Children's Hospital, Seattle
Pacific Pediatric Neuro-Oncology Consortium
OTHER
The V Foundation for Cancer Research
OTHER
University of California, San Francisco
OTHER